

August 7, 2014

# MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14, 2014

**MYOS Management Will Host a Conference Call and Webcast on Thursday, August 14, 2014 at 11:00 a.m. ET**

CEDAR KNOLLS, NJ -- (Marketwired) -- 08/07/14 -- [MYOS Corporation](#) ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging [biotherapeutics](#) and [bionutrition](#) company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it will release its financial results for the second quarter ended June 30, 2014, before the market opens on Thursday, August 14, 2014.

MYOS's management team will host a conference call and webcast for interested parties to discuss the financial results and provide a business update on Thursday, August 14, 2014 at 11:00 a.m. ET. Interested participants may access this conference call by dialing 877-407-7186 (U.S./Canada) or 201-689-8052 (International).

The webcast may be accessed via the [News and Events page](#) of the Investor Relations section of the MYOS corporate web site at [www.myoscorp.com](http://www.myoscorp.com), and will be archived for 30 days. Webcast participants are encouraged to go to the web site 15 minutes prior to the start of the call to register, download and install any necessary software.

## **About MYOS Corporation**

MYOS is a developmental stage biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin<sup>™</sup> ([MYO-T12<sup>®</sup>](#)), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"<sup>™</sup> visit [www.myoscorp.com](http://www.myoscorp.com).

The Company's first commercial product containing Fortetropin ([MYO-T12](#)), is distributed by Maximum Human Performance (MHP) under the brand name [MYO-X<sup>®</sup>](#) and is currently available on popular retailer websites including <http://mhpstrong.com>, [www.bodybuilding.com](http://www.bodybuilding.com), [www.amazon.com](http://www.amazon.com) and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

### ***Forward-Looking Statements***

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin<sup>™</sup> (MYO-T12<sup>®</sup>) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products including the proposed products described herein, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X<sup>®</sup>, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. The Company's products are not intended to diagnose, treat, cure or prevent any disease.

### ***MYOS Corporation Investor and Media Contact:***

Jenene Thomas  
Investor Relations and Corporate Communications  
(973) 509-0444  
[Email Contact](#)

Source: MYOS Corporation